TIDMDPH

RNS Number : 1755M

Dechra Pharmaceuticals PLC

17 September 2021

17 September 2021

Dechra(R) Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

The Company announces that on 16 September 2021 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive Plan:

 
 Name of individual    Director    Type of award       Number of shares 
                                                        subject to award 
                                   LTIP Award - 
 Ian Page              Director     nil cost option         23,727 
                      ----------  ------------------  ------------------ 
                                   LTIP Award - 
 Paul Sandland*        Director     nil cost option         11,000 
                      ----------  ------------------  ------------------ 
                                   LTIP Award - 
                                    conditional 
 Tony Griffin          Director     award                    6,508 
                      ----------  ------------------  ------------------ 
 

* Paul Sandland has also been granted a tax qualifying option over 330 shares at an exercise price of GBP49.09 as part of his LTIP award. This tax qualifying option is linked to the nil cost option such that, at the time of exercise, to the extent that there is a gain in the tax qualifying option, the nil cost option will be forfeited to the value of that gain.

The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Forms

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Ian Page 
     -----------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                Director 
     -----------------------------  ----------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                           Dechra Pharmaceuticals PLC 
     -----------------------------  ----------------------------------------- 
 b)   LEI code                       213800J4UVB5OWG8VX82 
     -----------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 1 pence each 
       the financial 
       instrument                     ISIN: GB0009633180 
 
       Identification 
       code 
     -----------------------------  ----------------------------------------- 
 b)   Nature of the                  Grant of awards over Ordinary Shares 
       transaction                    under the Company's Long Term Incentive 
                                      Plan 
     -----------------------------  ----------------------------------------- 
 c)   Price(s) and volumes(s)        Nil cost option 
                                       Price             Volume 
                                       Nil cost award    23,727 
                                                        ------- 
     -----------------------------  ----------------------------------------- 
 d)        Aggregated information 
             *    Aggregate volume     N/A 
 
                                       N/A 
 
             *    Price 
     -----------------------------  ----------------------------------------- 
 e)   Date of the transaction        2021-09-16 
     -----------------------------  ----------------------------------------- 
 f)   Place of the transaction       Outside a trading venue 
     -----------------------------  ----------------------------------------- 
 
 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Paul Sandland 
     -----------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                Director 
     -----------------------------  ----------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                           Dechra Pharmaceuticals PLC 
     -----------------------------  ----------------------------------------- 
 b)   LEI code                       213800J4UVB5OWG8VX82 
     -----------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 1 pence each 
       the financial 
       instrument                     ISIN: GB0009633180 
 
       Identification 
       code 
     -----------------------------  ----------------------------------------- 
 b)   Nature of the                  Grant of an award over Ordinary Shares 
       transaction                    under the Company's Long Term Incentive 
                                      Plan 
     -----------------------------  ----------------------------------------- 
 c)   Price(s) and volumes(s)        Nil cost option 
                                       Price             Volume 
                                       Nil cost award    11,000 
                                                        ------- 
 
 
                                      Tax qualifying option 
                                       Price                     Volume 
                                       GBP49.09 (per Ordinary 
                                        Share exercise price)    330 
                                                                ------- 
     -----------------------------  ----------------------------------------- 
 d)        Aggregated information 
             *    Aggregate volume     Awards granted over 11,330 Ordinary 
                                       Shares in total 
 
                                       N/A 
             *    Price 
     -----------------------------  ----------------------------------------- 
 e)   Date of the transaction        2021-09-16 
     -----------------------------  ----------------------------------------- 
 f)   Place of the transaction       Outside a trading venue 
     -----------------------------  ----------------------------------------- 
 
 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Tony Griffin 
     -----------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                Director 
     -----------------------------  ----------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                           Dechra Pharmaceuticals PLC 
     -----------------------------  ----------------------------------------- 
 b)   LEI code                       213800J4UVB5OWG8VX82 
     -----------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 1 pence each 
       the financial 
       instrument                     ISIN: GB0009633180 
 
       Identification 
       code 
     -----------------------------  ----------------------------------------- 
 b)   Nature of the                  Grant of an award over Ordinary Shares 
       transaction                    under the Company's Long Term Incentive 
                                      Plan 
     -----------------------------  ----------------------------------------- 
 c)   Price(s) and volumes(s)        Conditional award 
                                       Price             Volume 
                                       Nil cost award    6,508 
                                                        ------- 
     -----------------------------  ----------------------------------------- 
 d)        Aggregated information 
             *    Aggregate volume     N/A 
 
                                       N/A 
 
             *    Price 
     -----------------------------  ----------------------------------------- 
 e)   Date of the transaction        2021-09-16 
     -----------------------------  ----------------------------------------- 
 f)   Place of the transaction       Outside a trading venue 
     -----------------------------  ----------------------------------------- 
 

For further information, please contact:

Melanie Hall, Company Secretary

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharm aceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDCISBDGBR

(END) Dow Jones Newswires

September 17, 2021 06:52 ET (10:52 GMT)

Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Nov 2021 a Dic 2021 Clicca qui per i Grafici di Dechra Pharmaceuticals
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Dic 2020 a Dic 2021 Clicca qui per i Grafici di Dechra Pharmaceuticals